White Paper

Optimizing Your Clinical To Commercial Journey

By Michelle D’Angelo, Senior Director, Commercial Sales, and Tim Roberts, Chief Commercial Officer, PCI Pharma Services

GettyImages-1342134434 patient

What if you could eliminate avoidable delays and have a seamless transition from clinical trials to commercialization when launching your new drug? How should pharma and biopharma companies think about optimizing the journey from the development stage of clinical trials through to commercialization?

A key problem contributing to launch delays is the disconnect between the clinical development and commercialization teams. Much of that disconnect is because their goals are quite different: The focus of clinical development is clinical trial success and regulatory approval; while the goal of the commercial launch team is to bring new medicines to market with an acceptable unit cost that delivers on revenue goals, while also benefitting patients.

Yet, there is an opportunity to achieve the goals of both the clinical and commercial sides when they work together for the same purpose.

This white paper reviews:

  • Key Phase II to Phase III Considerations
  • Phase III to Commercialization Considerations
  • Package Development
  • Ensuring a Seamless Transition
  • Getting to Market as Fast as Possible
access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader